Disease resistance treatment fuels $50m investment

Research into developing new antimicrobial resistance treatment in Nigeria and other low/middle-income countries has fuelled a $50 million investment.

The Gates Foundation, Novo Nordisk Foundation, and Wellcome on Wednesday announced the launch of a $50 million investment that will focus on combating antimicrobial resistance (AMR).

The AMR is caused by a specific range of bacteria among the leading contributors to deaths.

The Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) will function as a consortium where multiple funders, research institutions and industry partners share data and work collectively to drive innovation in the discovery of new drugs.

The Gr-ADI is the first investment of the $300 million global health research and development partnership launched by these three philanthropic organisations last year.

The broader partnership will support science and innovation to advance solutions to health challenges that disproportionately impact people in low- and middle-income countries (LMICs).

These solutions include climate and sustainability; infectious diseases; and the interplay between nutrition, immunity, infectious diseases, cardiometabolic and other non-communicable diseases, and developmental outcomes.

“The AMR crisis continues to grow. We urgently need effective solutions to prevent a future of few to no treatments for drug-resistant infections,” said Alexander Pym, director of infectious disease at Wellcome. “Accelerating the discovery of new types of antibiotics and finding new ways to kill bacteria is key to tackling this global threat and protecting those in regions with the highest burden, such as Africa and Asia. Our best chance is to collaborate on innovative new approaches to antibiotic development.”

Read also: FG begins campaign against respiratory disease in Akwa Ibom

The AMR is a serious global health threat that is directly responsible for an estimated 1.14 million deaths a year, contributing to an additional 4.71 million deaths annually, and resulting in significant economic costs.

Despite this growing problem, the world faces an antibiotic pipeline marked by a shortage of new drugs and limited access to those that exist.

“Patients in Nigeria, where I live and work, and in other settings across Africa, Asia, South America, and the Caribbean that have resistant infections, do not have access to effective treatments and are also not well-placed to benefit from antimicrobial resistance innovations in the pipeline,” said Iruka Okeke, professor of pharmaceutical microbiology at the College of Medicine, University of Ibadan. “Moreover, Africa has the highest infectious disease burden, and resistant organisms spread rapidly across the continent, predominantly affecting the most vulnerable. This is why efforts like the Gr-ADI to innovate solutions to combat AMR caused by bacteria that disproportionately impact countries in Africa and other LMICs are so important.”

Bacterial AMR occurs when bacteria no longer respond to the antibiotics developed to combat them. This undermines the foundation of modern medicine by turning common infections and everyday procedures into potentially life-threatening situations.

“Bacterial AMR is such a significant global health issue that we must speed up innovation and try new ways of working together,” said Marianne Holm, vice president, infectious diseases at the Novo Nordisk Foundation. “Through the Gr-ADI program, grant recipients will not only focus on their projects but will also become integral members of a consortium dedicated to data sharing, with a focus on specific Gram-negative bacteria. For many researchers involved in this program, it will be a new way of working, but we believe that it can make a big difference as we search for new discoveries.”

Projects funded through the Gr-ADI will be selected by the partners through a request for proposals (RFP) that leverages the Gates Foundation’s Grand Challenges platform, an initiative that has fostered innovation to solve key global health and development problems for more than 20 years.

The focus of this RFP will be on the discovery of antibiotics with broad-spectrum activity against Enterobacteriaceae, the Gram-negative family of bacteria that includes Klebsiella spp., which is the pathogen that should be used in proposed projects.